Welcome to the Oncology Brothers podcast! In this episode, we dived into a challenging case series focused on kidney cancer, featuring special guest Dr. Pedro Barata, a GU medical oncologist from the University Hospitals.
We had the opportunity to explore two real-life cases that highlighted the complexities of treatment decisions in metastatic renal cell carcinoma (RCC). We discussed the latest frontline options, including immunotherapy and targeted therapy combinations, and how to choose the best approach based on patient characteristics and disease progression.
Key topics covered in this episode included:
The role of next-generation sequencing (NGS) in guiding treatment options
Choosing between dual checkpoint inhibitors and IO-TKI combinations
Managing side effects associated with various treatment regimens
Sequencing treatment options for patients who progress after initial therapy
Insights into the latest data on emerging therapies like Belzutifan and Lenvatinib
Podden och tillhörande omslagsbild på den här sidan tillhör
Oncology Brothers. Innehållet i podden är skapat av Oncology Brothers och inte av,
eller tillsammans med, Poddtoppen.
